Quarter wasn’t that bad given everything happening over the past year. Business will stabilize and grow in the second half of the year. A second way to finance/try before you buy should help introduce the product to more clinics. The disposables income should continue growing and International success isn’t baked into the numbers yet.
Share price compliance is the wildcard. $83mm in cash with no debt. A buyback would make sense if they are projecting cash burn to remain at historical levels. I think they could even have positive cash flow in the next 12 months. Companies never buy their own stock when it’s cheap.
Market Data 
Markets 
